Rational Drug Pricing
huffingtonpost.com
huffingtonpost.com
Generic drugs don’t need the excruciatingly drawn-out safety and efficacy studies required of new brand-name medications, but they do need to pass a bioequivalency study proving that their drug is absorbed the same way as the original. ... it’s just too hard to start making a generic medication. If all you want to do is synthesize an active ingredient in powder form, and you’re not too concerned about staying on the right side of the law, it costs pennies and takes however long you need to FedEx something from China. If you also want FDA approval, it costs $2 million and takes two years.
Remember, Daraprim is used by about 10,000 people per year, and before the recent Turing price markup, it cost $13.50 per pill x eighty pills per treatment. 10,000 x 80 x $13.50 = about $10 million per year, of which maybe $5 million was profit. That means you have to capture a big chunk of the Daraprim market before it’s worth trying to get yourself approved to make Daraprim; the FDA is essentially telling pharma companies to “go big or go home”. Nobody wanted to go big, so they all went home.
In the absence of this barrier, it would be easy for small boutique companies with a couple of chemical engineers on hand to spend a few weeks manufacturing a few thousand doses of the drug whenever it was necessary to meet demand. This is how the supplement and nootropic industries work right now, and nootropics are dirt cheap
- http://slatestarcodex.com/2015/09/24/the-problems-with-gener...
(and if you don't read SlateStarCodex regularly, this is a good time to start)
Gilead did something that was once considered far off - they created a CURE for Hepatitis C. Because they created a cure, we are infinitely better off in that regard - before there were 0 people getting reliably cured, now there is a number greater than 0 getting reliably cured of hepatitis C.
In 20 years, the patent will expire and whoever wants to can make this for free if they want.
I propose the following compromise. Let the government create and fund a biomedical research lab for creating new drugs. The process for drug approval should be the exact same as for everyone else. Any drug that the government's lab discovers and gets approved can be given away or whatever the government wants. Any drug not discovered by them, they should let the companies that actually discovered the drug set the prices.
This is hacker news created by YCombinator. Will a VC fund a startup whose best case return is 10x investment? Would we rather have more money/effort invested in curing disease or making "sharing economy" apps? I think companies that do save lives should have outsize rewards. For government to step in and try to change that would be killing the goose that lays the golden egg.
The regulatory failure is the VA system being unwilling to pay for it (assuming that's true), not the perfectly reasonably priced drug that's cheaper than alternative, less effective treatments.
- There is no reason the US should be giving away IP for free
- The US Government should use its purchasing power as a check against the drug companies
- Drug companies should be able to reap profits, but profits at a 10-20x P/E not 100x
Says it's 10.20 as I enter this.
At least one of which is implied in the Wikipedia article, also see their current pipeline, some of those are going to fail, and at the end their 22 failures to date. 1 in Phase III trials ($$$, efficacy, the most expensive), 5 in Phase II (fairly expensive, I think), 5 in Phase I (certainly not "cheap").
It sure looks like they're doing the right thing with their science and medicine, their founder was motivated by having contracted deng fever, which is untreatable (besides of course supportive measure). Clearly the right thing to do is to beat them up the few times they hit it out of the ballpark with a "100x" success, that'll teach them and the other drug companies!
This times a million. If you fix that, most of the drug problem goes away here in the US even if you don't start letting Medicaid bargain.